EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are main treatment for patients with advanced NSCLC with EGFR exon 19 deletion or exon 21 substitution [36],[37].